It has been shown in multiple tumors, indexes such as PD‐L1 positivity, dMMR/MSI, and EBV infection are benefitable biomarkers from ICI therapy, yet TMB has not been considered valid in instructing immunotherapy in GC.59, 60, 61. This evidence concerns the gene CD274 and gastric cancer.